How Can Pharmacists Support Patients Being Treated with Orphan Drugs?

Gordon Vanscoy, PharmD, MBA, explains the challenges patients face when being treated with orphan drugs, and how pharmacists can help overcome these challenges.


Orphan drugs present a unique set of challenges to society, because there’s such small populations. An orphan drug is less than a population of 200,000, an ultra-orphan drug is less than 2,000 people. These small populations, in order to get them onto the market takes a lot of investment, and obviously they become very expensive products. So, once they are released it’s our challenge to not only get the drug and provide care to these people, but find them finical resources so they can actually afford it. It can be a tremendous burden for these patients and that’s a big responsibility for us to point them in the right direction.

Most Popular

Related Articles

In this clip, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx Specialty Pharmacy, explains how orphan drugs are making an impact on patients in the era of precision medicine.
In this video, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx, describes the methods of patient support used by PantheRx throughout treatment to provide optimal care.
Dallas-based Senderra Rx achieves perfect net promoter score.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.